Interaction between methylphenidate, methadone and different antidepressant drugs on antinociception in mice, and possible clinical implications

References

• Aga-Mizrachi S, Cymerblit-Sabba A, Gurman O, Balan A, Shwam G, Deshe R, et al. 2014. Methylphenidate and desipramine combined treatment improves PTSD symptomatology in a rat model. Transl Psychiatry 4:e447
   Google Scholar
• Angold A, Costello EJ, Erkanli A. 1999. Comorbidity. J Child Psychol Psychiatry 40:57–87.
   PubMed Web of Science ®Google Scholar
• Arias AJ, Gelernter J, Chan G, Weiss RD, Brady KT, Farrer L, et al. 2008. Correlates of co-occurring ADHD in drug-dependent subjects: prevalence and features of substance dependence and psychiatric disorders. Addict Behav 33:1199–1207.
   PubMed Web of Science ®Google Scholar
• Brookshire BR, Jones SR. 2012. Chronic methylphenidate administration in mice produces depressive-like behaviors and altered responses to fluoxetine. Synapse 66:844–847.
   PubMed Web of Science ®Google Scholar
• Carpentier PJ, van Gogh MT, Knapen LJ, Buitelaar JK, De Jong CA. 2011. Influence of attention deficit hyperactivity disorder and conduct disorder on opioid dependence severity and psychiatric comorbidity in chronic methadone-maintained patients. Eur Addict Res 17:10–20.
   PubMed Web of Science ®Google Scholar
• Charach A, Yeung E, Climans T, Lillie E. 2011. Childhood attention-deficit/hyperactivity disorder and future substance use disorders: comparative meta-analyses. J Am Acad Child Adolesc Psychiatry 50:9–21.
   PubMed Web of Science ®Google Scholar
• Crawford CA, Villafranca SW, Cyr MC, Farley CM, Reichel CM, Gheorghe SL, et al. 2007. Effects of early methylphenidate exposure on morphine- and sucrose-reinforced behaviors in adult rats: relationship to dopamine D2 receptors. Brain Res 1139:245–253.
   PubMed Web of Science ®Google Scholar
• Frauger E, Nordmann S, Orleans V, Pradel V, Pauly V, Thirion X, et al. 2012. Which psychoactive prescription drugs are illegally obtained and through which ways of acquisition? About OPPIDUM survey. Fundam Clin Pharmacol 26:549–556.
   PubMed Web of Science ®Google Scholar
• Greenhill LL, Pliszka S, Dulcan MK, Bernet W, Arnold V, Beitchman J, et al. 2002. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41:26S–49S.
   PubMed Web of Science ®Google Scholar
• Halladay LR, Iñiguez SD, Furqan F, Previte MC, Chisum AM, Crawford CA. 2009. Methylphenidate potentiates morphine-induced antinociception, hyperthermia, and locomotor activity in young adult rats. Pharmacol Biochem Behav 92:190–196.
   PubMed Web of Science ®Google Scholar
• Invernizzi RW, Parini S, Sacchetti G, Fracasso C, Caccia S, Annoni K, et al. 2001. Chronic treatment with reboxetine by osmotic pumps facilitates its effect on extracellular noradrenaline and may desensitize alpha(2)-adrenoceptors in the prefrontal cortex. Br J Pharmacol 132:183–188.
   PubMed Web of Science ®Google Scholar
• Karlstad Ø, Furu K, Skurtveit S, Selmer R. 2014. Prescribing of drugs for attention-deficit hyperactivity disorder in opioid maintenance treatment patients in Norway. Eur Addict Res 20:59–65.
   PubMed Web of Science ®Google Scholar
• Koda K, Ago Y, Cong Y, Kita Y, Takuma K, Matsuda T. 2010. Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. J. Neurochem. 114:259–270.
   PubMed Web of Science ®Google Scholar
• Kollins SH. 2007. Abuse liability of medications used to treat attention-deficit/hyperactivity disorder (ADHD). Am J Addict 16:35–42.
   PubMed Web of Science ®Google Scholar
• Kollins SH. 2008. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders. Curr Med Res Opin 24:1345–1357.
   PubMed Web of Science ®Google Scholar
• Levin FR, Evans SM, Brooks DJ, Kalbag AS, Garawi F, Nunes EV. 2006. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend 81:137–148.
   PubMed Web of Science ®Google Scholar
• Mariani JJ, Levin FR. 2007. Treatment strategies for co-occurring ADHD and substance use disorders. Am J Addict 16:45–56.
   PubMed Web of Science ®Google Scholar
• Peles E, Schreiber S, Linzy S, Domani Y, Adelson M. 2015. Differences in Methylphenidate Abuse Rates Among Methadone Maintenance Treatment Patients in Two Clinics. J Subst Abuse Treat 54:44–49.
   Google Scholar
• Peles E, Schreiber S, Naumovsky Y, Adelson M. 2007. Depression in methadone maintenance treatment patients: rate and risk factors. J Affect Disord 99:213–220.
   PubMed Web of Science ®Google Scholar
• Pick CP, Paul D, Eison MS, Pasternak GW. 1992. Potentiation of opioid analgesia by the antidepressant nefazodone. Eur J Pharmacol 211:375–381.
   PubMed Web of Science ®Google Scholar
• Rust KY, Baumgartner MR, Dally AM, Kraemer T. 2012. Prevalence of new psychoactive substances: A retrospective study in hair. Drug Test Anal 4:402–408.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Getslev V, Weizman A, Pick CG. 1998. The antinociceptive effect of moclobemide in mice is mediated by noradrenergic pathways. Neuroscience Letters 253: 183–186.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Backer MM, Pick CG. 1999. The antinociceptive effect of venlafaxine in mice is mediated through opioid and adrenergic mechanisms. Neuroscience Letters 273:85–88.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Backer MM, Herman I, Shamir D, Rigai T. Bar-Hamburger, et al. 2003. Mianserin and Trazodone Significantly Attenuate the Intensity of Opioid Withdrawal Symptoms in Mice. Addiction Biology 8:107–114.
   PubMedGoogle Scholar
• Schreiber S, Pick CG. 2006. From selective to highly-selective SSRIs: A comparison of the antinociceptive properties of fluoxetine, fluvoxamine, citalopram and escitalopram,. Eur Neuropsychopharmacol 1630:464–468.
   Web of Science ®Google Scholar
• Schreiber S, Frishtick R, Volis I, Rubovitch V, Pick CG, Weizman R. 2009. The antinociceptive properties of reboxetine in acute pain. Eur Neuropsychopharmacol 19:735–739.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Barak Y, Hostovsky A, Baratz-Goldstein R, Volis I, Rubovitch V, et al. 2014. Interaction of different antidepressants with acute and chronic methadone in mice, and possible clinical implications. J. Mol. Neurosci. 52:598–604.
   PubMed Web of Science ®Google Scholar
• Schubiner H. 2005. Substance abuse in patients with attention-deficit hyperactivity disorder: therapeutic implications. CNS Drugs 19:643–655.
   PubMed Web of Science ®Google Scholar
• Semeijn EJ, Comijs HC, Kooij JJ, Michielsen M, Beekman AT, Deeg DJ. 2015. The role of adverse life events on depression in older adults with ADHD. J Affect Disord 174:574–579.
   PubMed Web of Science ®Google Scholar
• Seo DO, Shin CY, Lee CJ, Dailey JW, Reith ME, Jobe PC. 1999. Effect of alterations in extracellular norepinephrine on adrenoceptors: a microdialysis study in freely moving rats. Eur J Pharmacol 365:39–46.
   PubMed Web of Science ®Google Scholar
• Sobanski E. 2006. Psychiatric comorbidity in adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci 256:i26–i31.
   PubMed Web of Science ®Google Scholar
• Tanda G, Frau R, Di Chiara G. 1996. Chronic desipramine and fluoxetine differentially affect extracellular dopamine in the rat prefrontal cortex. Psychopharmacology 127:83–87.
   PubMed Web of Science ®Google Scholar
• Weikop P, Yoshitake T, Kher J. 2007. Differential effects of adjunctive methylphenidate and citalopram on extracellular levels of serotonin, noradrenaline and dopamine in the rat brain. Eur Neuropsychopharmacol 17:658–671.
   PubMed Web of Science ®Google Scholar
• Wilens TE. 2004. Attention-deficit/hyperactivity disorder and the substance use disorders: the nature of the relationship, subtypes at risk, and treatment issues. Psychiatr Clin North Am 27:283–301.
   PubMed Web of Science ®Google Scholar
• Wiley MD, Poveromo LB, Antapasis J, Herrera CM, Bolaños Guzmán CA. 2009. Kappa-opioid system regulates the long-lasting behavioral adaptations induced by early-life exposure to methylphenidate. Neuropsychopharmacology 34:1339–1350.
   PubMed Web of Science ®Google Scholar
• Wilkins C, Sweetsur P, Griffiths R. 2011. Recent trends in pharmaceutical drug use among frequent injecting drug users, frequent methamphetamine users and frequent ecstasy users in New Zealand, 2006-2009. Drug Alcohol Rev 30:255–263.
   PubMed Web of Science ®Google Scholar
• Zhu J, Spencer TJ, Liu-Chen LY, Biederman J, Bhide PG. 2011. Methylphenidate and μ opioid receptor interactions: a pharmacological target for prevention of stimulant abuse. Neuropharmacology 61:283–292.
   PubMed Web of Science ®Google Scholar